---
title: "Immunoglobulin Industry Size by 2029: Demand and Regional Analysis"
datePublished: Fri Mar 10 2023 08:48:25 GMT+0000 (Coordinated Universal Time)
cuid: clf2apn05000009le6beca06y
slug: immunoglobulin-industry-size-by-2029-demand-and-regional-analysis
tags: news, google, hashnode, linkedin

---

The size of the [global immunoglobulin market,](https://www.fortunebusinessinsights.com/industry-reports/immunoglobulins-market-100571) estimated at USD 13.70 billion in 2021, is expected to increase by USD 8.5% annually from 2022 to 2029, from USD 14.51 billion to **USD 25.63 billion.** According to our analysis, the global market grew **4.2%** less slowly in 2020 than it did in 2019. The demand for immunoglobulin was lower than expected in all regions compared to pre-pandemic levels during the unprecedented and staggering COVID-19 pandemic.

**Access Full Report Page:** [https://www.fortunebusinessinsights.com/industry-reports/immunoglobulins-market-100571](https://www.fortunebusinessinsights.com/industry-reports/immunoglobulins-market-100571)

**Market Driver**: **Introduction of Advanced Therapeutic to Augment Growth**

The launch of novel advanced drugs such as CUVITRU and BIVIGAM by Shire (Takeda Pharmaceutical Company Limited) and ADMA Biologics Inc., respectively will impel manufacturers to innovative drugs and give competition to the rival companies, which, in turn, will spur opportunities for the market. The increasing adoption of immunoglobulin therapy as the first line of treatment for primary immunodeficiency and other rare immunological and neurological diseases will be a critical factor in promoting the growth of the market.

The growing focus on the diagnosis of immune disorders will foster the healthy growth of the market. The increasing prevalence of numerous viruses and diseases has led to pre-diagnosis, which, in turn, will augur well for the market. The growing efficiency of immunoglobulin as an effective treatment option for several diseases such as primary immunodeficiency and chronic inflammatory demyelinating polyneuropathy (CIDP) will positively enable speedy expansion of the market in the foreseeable future.

**Regional Analysis**:

**Rising Patient Population to Aid Expansion in North America**

The market in North America generated a revenue of US$ 6,291.5 Mn in 2017 and is and is predicted to remain dominant during the forecast period. The growth in the region is attributed to the acceptance of immunoglobulin as a first line of treatment for many critical immune disorders. The increasing number of patients and the growing demand for novel therapies will further aid the growth of the market in the region.

**Request a Sample Copy of the Research Report:** [https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/immunoglobulins-market-100571](https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/immunoglobulins-market-100571)

Asia Pacific is predicted to hold the largest share in the market owing to the demand for intravenous (IV) in developing nations. The increasing healthcare expenditure and rising investment for advanced immunoglobulins will further enable growth in the region. The Middle and Africa is likely to expand in the forthcoming years owing to the developing healthcare infrastructure in the region.